AbilityPharma is a biopharmaceutical company focused on creating the future of oncology by developing innovative therapies that address unmet medical needs. The company was established in 2009 with one product, ABTL0812, an oral autophagy-inducer targeted therapy in phase 2 clinical trials in patients with endometrial cancer and in squamous NSCLC.